India virus vaccine Volunteers India

'Sometimes I get goosebumps,' says Bharat Biotech MD as firm preparing for Covaxin rollout

Reading now: 474
www.livemint.com

Emergency UsageBharat has spent about $60 million to $70 million so far developing Covid vaccines, and early trial data suggest Covaxin, an inactivated candidate that uses a dead version of the virus, has efficacy rates of at least 60%, which Ella said was a “conservative" projection.That may improve in the final human study, she said.

The trial has recruited half of its 26,000 volunteers, and going into 2021 Ella expects licensing to allow inoculations for public use by May or June.The lack of phase III trial data didn’t stop Bharat from applying for emergency use authorization this month, though the company and Serum Institute -- which has submitted final phase numbers -- have been asked by Indian regulators to provide additional figures.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA